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INTRODUCTION 
Autoimmune diseases are chronic diseases which are 
caused by the loss of the body's immunological tolerance 
to its self-antigens. Chronic nature of these diseases has a 
noticeable impact on the use of medical care and services 
directly or indirectly by economic costs and affecting the 
quality of life. The prevalence of autoimmune diseases is 
estimated about 90 cases per 100,000 people annually 
and the incidence rate of them is estimated at 3% of the 
whole population.1 
Systemic sclerosis (SSc) is one of chronic multi-systemic 
autoimmune and idiopathic diseases, which occurs due to 
excessive collagen deposition and production of 
autoantibodies in the skin, internal organs and 
vasculopathy of small vessels.2 
The prevalence of SSc varies from 100 to 300 people per 
million people worldwide and its incidence is about 20 
cases per million people.3 
Marie, in a study in 2006, showed that anorectal 
involvement is prevalent to the extent of 50%-70%, and 
digestive symptoms develop up to 75%-90% among 
patients with two main subtypes of SSc i.e, limited and 
diffuse SSc.4 In a study by Jaovisidha et al, it has been 
explored that 80% of patients had diffuse SSc and 20% 
had limited SSc. Moreover, they have found that the 
gastrointestinal involvement in SSc can be extremely 
debilitating and even life threatening.5 
Tian et al have undertaken a study and have shown that 
SSc diagnosis is based on manometry and endoscopic 
examination and treatment, besides, they have expressed 
that supportive and symptomatic treatment is the best 
strategy. However, they have suggested early diagnosis 
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as a determining factor in successful management of the 
disease.
6
 
The involvement of gastrointestinal tract as an important 
part of the body occurs in about 90% of patients and SSc 
disease is involved from beginning to end includes 
inflammation, vascular damage due to ischemia, fibrosis 
and neuropathy in the upper and lower parts of the 
gastrointestinal tract.7-9 
Totally speaking, there are a number of ways to treat the 
disease such as immunosuppressive therapy, anti-fibrotic 
therapy, treatment of intestinal complications, treatment 
of gastrointestinal complications, and treatment of 
pulmonary hypertension and systemic blood pressure. 
Probiotics are live non-pathogenic microorganisms 
(bacteria and yeasts) that cause adequacy of microflora 
in the intestines of host.10,11 
The probiotics are helpful in IBS in which the abnormal 
functions of the gastrointestinal tract concerning motility 
and viscera, and the intestinal tract's hypersensitivity are 
dependent on psychosocial factors. 
The theory of the role of probiotics in replacing the 
intestinal harmful flora with beneficial flora and 
alleviating the symptoms of SSc, especially bloating and 
abdominal distention has led to the use of probiotics for 
SSc patients who develop symptoms. It is necessary to 
note that the intestinal microflora can play a modifying 
role in the immune system.12 
Considering frequency of gastrointestinal symptoms in 
patients with systemic sclerosis, the aim of this study 
was to investigate the effect of probiotics in treating the 
symptoms in patients with SSc. 
METHODS 
This clinical trial study was conducted over 37 patients 
with SSc who had been diagnosed in the Tehran's 
Rheumatology Clinic in 2014. The sample was randomly 
divided into two groups of control (17 persons), and 
intervention (20 persons). Randomization was performed 
as randomized blocking to eliminate the effect of 
nuisance factors. 
In the beginning, the patients were examined and their 
gastrointestinal symptoms and other necessary 
information were recorded by the researcher. 
Subsequently, UCLA SCTC GIT 2.0 questionnaire was 
administered among patients. This questionnaire 
consisted of 7 scales of reflux, abdominal 
distension/bloating, fecal soilage, diarrhea, emotional 
disorders, and social functioning, and constipation that 
were used to elicit information from the patients. The 
patients were asked about the occurrence of symptoms 
over the last week. The obtained mean score for 7 scales 
was the criterion to judge the change in the situation 
before and after taking the drug. Those patients 
developing moderate to severe symptoms of systemic 
sclerosis who had scores higher than1.25, were included 
in the study. Then, lactobacillus casei probiotic, in the 
form of tablets, were given to the patients to take for two 
months. Two months later, the patients were re-examined 
and completed the same questionnaire, and the recorded 
data were compared and analysed before and after 
intervention. 
The patients were told not to make any change in their 
medicinal, nutritional, or behavioural pattern. Related to 
blinding, probiotic was prepared in packages similar to 
placebo and patients and therapists were unaware of 
which group they were allocated. Exclusion criteria 
involved not taking the drug on time, drug intolerance 
due to side effects, or incompatibility of the patient's taste 
with the drug, and the patient's unwillingness to 
participate in the study.  
Statistical analysis 
The gathered data from the check-lists and test results 
were entered into the SPSS16 and were analysed using t-
test and non-parametric test of Mann-Whitney U-test. In 
the present study, the patients were not imposed any extra 
charge. The used examinations in this study were regular 
techniques that were accepted in the scientific and 
international assemblies. Before undertaking study, 
informed written consent form was obtained from all the 
patients. 
RESULTS 
Figure 1: The average of esophageal reflux score in 
two groups after intervention. 
The total number of participants in the study was 37, 
including 20 SSc patients in the intervention group, and 
17 SSc patients in the control group. Of all the patients, 
32 patients (86.5%) were females and 5 patients (13.5%) 
were males. Both of control and intervention groups 
were similar in terms of sex. The disease duration ranged 
from 1 to 16 years with the mean of 6 years and the 
standard deviation of 3.41 years. The age range of the 
patients was between 18 and 58 years with the mean age 
of 46.3 and the standard deviation of 11.8. Prednisolone 
taken by 34 patients (92%) and omeprazole taken by 29 
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patients (85%) were the most common drugs used by the 
patients.  
Two months after taking probiotics, a significant 
difference was observed between the mean score for 
esophageal reflux in the intervention group (mean 0.91, 
standard deviation 0.52) and the control group (mean 
1.89, standard deviation 0.55), while the difference 
between groups was not significant prior to the 
intervention (Figure 1). 
Two months after taking probiotics, abdominal 
distension's mean score between the intervention groups 
(mean 0.7, standard deviation 0.49) and the control group 
(mean 1.89 standard deviation 0.38) showed a significant 
difference, but the difference was not significant before 
the intervention (Figure 2). 
Figure 2: The average of gastric distention score in 
two groups after intervention. 
The mean of fecal incontinence scores for the 
intervention group (mean 0.037, standard deviation 0.16) 
and the control group (mean 0.058 standard deviation 
0.25) didn't show statistically significant difference. 
Similarly, the difference between average score of 
diarrhea in the intervention groups (mean 0.4, standard 
deviation 0.5) and in the control group (mean 0.38, 
standard deviation 0.51) was not statistically significant. 
Figure 3: The average of social performance score in 
two groups after intervention. 
The difference between average score of social 
functioning in the intervention group (mean 0.33, 
standard deviation 0.36) and the control group (mean 
0.78, standard deviation 0.41), was statistically 
significant, considering that there was no significant 
difference in this regard between groups before the 
intervention (Figure 3). 
Two months after taking probiotics, the mean score of 
emotional disorders didn't vary significantly from the 
intervention group (mean 1.11, standard deviation 0.56) 
to the control group (mean 2.14, standard deviation 0.44) 
(Figure 4). 
Figure 4: The average of emotional disorder score in 
two groups after intervention. 
The average score of constipation for two groups of 
intervention (mean 0.55, standard deviation 0.77), and 
control (mean 0.58, standard deviation 0.63) didn't differ 
significantly. 
Two months after taking probiotics, the difference 
between mean of total scores in the intervention group 
(mean 0.68, standard deviation 0.38) and the control 
group (mean 1.29 standard deviation 0.29) was not 
statistically significant (Figure 5). 
Figure 5: The average of total score in two groups 
after intervention. 
DISCUSSION 
Scleroderma or systemic sclerosis (SSc) is a connective 
tissue disorder and autoimmune disease that cause skin 
and internal organs like gastrointestinal tract to be 
affected. Scleroderma is a chronic inflammatory disease 
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that produces a variety of symptoms through different 
mechanisms. The symptoms of this disease appear in 
various systems of body and different medications are 
used to relieve them. In the gastrointestinal tract 
depending on the symptoms that occur, suitable 
medication is prescribed for the patient. As mentioned in 
the introduction, slow gastrointestinal motility brings on 
gastroesophageal reflux. To treat this problem various 
medicines, such as pump inhibitor drugs like omeprazole 
are prescribed. 
Besides, constipation as other problem also arises that 
some medicines like cisapride or domperidone are 
prescribed to increase motility and treat the problem. In 
any case, these drugs because of their side effects may 
not be used by patients or bring about some problems for 
them in the long run. In the recent years, researchers and 
specialists are looking for drugs that have fewer side 
effects and at the same time are more effective. And it 
was why probiotics were introduced to this area. The 
mean scores of reflux, abdominal distension, social 
functioning, emotional disorders, and total score in the 
intervention and the control groups were significantly 
different from each other, suggesting that the use of 
probiotics could reduce gastrointestinal symptoms in the 
intervention group. 
In the same study Firch and et al in America, showed that 
4 scales of the esophageal reflux, abdominal distension, 
emotional disorders and the average total score reduced 
significantly. In this study, in addition to above four 
aspects, the patients' social functioning improved as well, 
while in the Firch et al study there was no improvement 
in this regard.
13
 
The results of Capello's study in Italy on symptoms of 
patients with irritable bowel syndrome have shown that 
the amount of bloating and feeling flatulence 
significantly decreased by taking probiotics, which is in 
line with the present study's finding.
14 
Pourfarzi et al in a study over patients with irritable 
bowel syndrome who had consumed probiotics for four 
weeks, reported that abdominal pain and bloating of 
patients significantly alleviated, this finding also 
confirms the results obtained in the present study.
15
 
Several studies have shown that gastrointestinal tract is 
involved in 70-90% of patients with SSc. A recent study 
by Schmeiser and colleagues displayed that 98.9 patients 
with SSc are suffering from gastrointestinal discomfort. 
Generally, the severity of gastrointestinal symptoms from 
mild to severe are pain, dysphagia, nausea, diarrhea, 
constipation and fecal incontinence. The results of above 
studies are consistent with the results of this study in 
which all patients had gastrointestinal involvement.
16-20
 In 
this study, the duration of disease varied from 1 to 16 
years with the mean of 6 years and the standard deviation 
of 3.41 years, which was less than the average duration of 
disease reported in Al-Dhaher et al's study. In Al-Dhaher 
et al's study, the duration of SSc was considered until the 
last visit or the death of patient which was 9.1 years (7 .9 
years in diffuse SSc, and 9.8 in limited SSc). Moreover, it 
was also revealed that cardiac involvement, dcSSc and 
hypertension are associated with poor survival.
21
 In the 
present study, the survival of patients with scleroderma 
improved compared to previous reports in other studies.  
CONCLUSION 
This study is among the first studies undertaken on the 
role of probiotics in patients with SSc in Iran, and one the 
rare studies conducted in the world. The high power 
(0.99) and the large sample size of this study are the 
strong points of the present study. It is worth mentioning 
that since probiotics are harmless, they can be consumed 
along with other medications that scleroderma patients 
receive.  And in the case of being effective, taking other 
medicines with gastrointestinal side effects can be 
reduced gradually. It is suggested that systematic studies 
and meta-analysis to be conducted on the effect of 
probiotics on gastrointestinal symptoms in patients with 
scleroderma, and in the case of yielding better results to 
be used as alternative way for treating the gastrointestinal 
symptoms in these patients.  
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